about
Recent advances in phototherapy for psoriasisThe Patient's Guide to Psoriasis Treatment. Part 4: Goeckerman TherapyThe Patient's Guide to Psoriasis Treatment. Part 3: Biologic InjectablesThe Patient's Guide to Psoriasis Treatment. Part 2: PUVA PhototherapyThe Patient's Guide to Psoriasis Treatment. Part 1: UVB PhototherapyBrodalumab for the Treatment of Psoriasis: A Review of Phase III TrialsIxekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsDemyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review.Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule.Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey.Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple SclerosisClinical skills development in student-run free clinic volunteers: a multi-trait, multi-measure studyThe role of IL-17 in vitiligo: A reviewInfluence of diet on the gut microbiome and implications for human health.Comparison of photodermatoses in African-Americans and Caucasians: a follow-up study.The Role of the Nervous System in the Pathophysiology of Psoriasis: A Review of Cases of Psoriasis Remission or Improvement Following Denervation Injury.Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review.Phototherapy for the treatment of prurigo nodularis: a review.Drug-Induced Tactile Hallucinations Beyond Recreational Drugs.Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision.Erratum: Clinical skills development in student-run free clinic volunteers: a multi-trait, multi-measure study.Monoclonal gammopathy of undetermined significance and fatal polyarteritis nodosa.Obsessive-compulsive skin disorders: a novel classification based on degree of insight.Uremic pruritus treated successfully with the Goeckerman Program.Personality disorders and the "difficult" dermatology patient: Maximizing patient satisfaction.Successful use of a modified Goeckerman regimen in the treatment of chronic severe atopic dermatitis: A prospective pilot study.Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation.An analysis of 72% chromated glycerin used for sclerotherapy: sterility, potency, and cost after extended shelf life.Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling ruleHome phototherapy for patients with vitiligo: challenges and solutionsSafety considerations with combination therapies for psoriasisUse of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case reportNarrowband UVB-induced iatrogenic polymorphous light eruption: a case and suggestions to overcome this rare complication
P50
Q26738629-2A365AE7-C673-4B67-81FB-062AD72C91D0Q26740445-3F418BD8-C835-46B7-82A7-38CBA9404E9DQ26740450-0F0AA4EB-C384-4711-81FA-F5A1E85D045CQ26740455-DC84DE5E-524F-42D6-B45E-BEEF3331C714Q26740460-46CE3AE1-2FDA-4D0A-93C0-9B0989C0C450Q26746100-BDA55DA9-B3C3-48A7-A8B6-D7C5943107A6Q26766567-D214A8C5-5800-4E33-BF16-9B6B70712E8EQ30251926-66A77390-83DD-4F4E-A470-A27AB4894396Q31054536-91BBA83B-B29A-47B2-BEDF-B0FFE1586908Q33623762-70122837-BE76-4B4D-9B04-C8BE4FCF9E7DQ33752746-E66096EF-8466-4811-A8CC-7BFF03CACE84Q34376935-4BC7AD2A-BC1D-468C-B564-8A6357BE4E7DQ34712425-4CA5764A-0B5E-4B59-B18B-6F3796C04AB2Q36625953-EE989669-EA81-4096-AF0D-8EB79261D328Q37742351-D7700B3C-FC2C-43D5-8FDB-27DD5C9FFC4BQ38151927-0F99F3E9-8C36-432B-BE53-172BC9B2F90FQ38758398-7F4C1681-18A0-4B28-8F85-23EA78A91074Q38939797-56C7A3E6-5C0D-41A4-923C-1FA6DF783A92Q38951740-61C11986-EB76-4ED0-A6CC-B6524D78012FQ38956733-DD6CC3A8-D57F-436F-BD26-C2115EE27070Q39152793-8E7E9C48-482D-4614-BDB4-BBC51E70A298Q42365054-E5DBC41E-F68D-453A-B7F6-654FAD1F4F05Q43677732-F9135C78-CC1C-4C65-B7C7-31A5D6FB66EEQ45986571-703227F8-8839-4F0C-8C47-B81C4A15B51DQ46391426-FC1A9DC6-D380-49F4-9631-4694381016A0Q46409581-4DF826F9-1F8B-40CE-B976-52AF0B5C26D3Q46639554-6163C618-9C52-413B-960A-515F86007835Q50943872-4CB8B6A7-0398-48E2-9186-3BE0AE349BA5Q53658502-1A537DBD-AE51-44C1-90FB-F631A1CBE925Q88035551-A187022F-BEDE-41FA-9F61-99D504C7A64FQ92462193-469ECAA3-15A7-4E62-9915-2EC4D9FBC052Q92962121-001DF655-C0D6-4087-96DC-3AE19C4F7536Q95525994-3EF53E2C-BBE1-442C-8171-BEE59E8FC082Q95526981-E1A48A29-880C-422C-9521-9E2FC94CF57E
P50
description
dermatoloog
@nl
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Mio Nakamura
@ast
Mio Nakamura
@de
Mio Nakamura
@en
Mio Nakamura
@es
Mio Nakamura
@nl
Mio Nakamura
@sl
type
label
Mio Nakamura
@ast
Mio Nakamura
@de
Mio Nakamura
@en
Mio Nakamura
@es
Mio Nakamura
@nl
Mio Nakamura
@sl
prefLabel
Mio Nakamura
@ast
Mio Nakamura
@de
Mio Nakamura
@en
Mio Nakamura
@es
Mio Nakamura
@nl
Mio Nakamura
@sl
P227
P21
P214
7597153954906305680006
P227
116865825X
P31
P496
0000-0002-1367-742X
P734
P735
P7859
viaf-7597153954906305680006